It was a cheerful sunny Easter Sunday when my wife and I chose to undergo an elective induction at 39 weeks gestation based on our obstetrician’s (OB’s) recommendation, a recommendation that was based on a recent NEJM (New England Journal of Medicine) study named the ARRIVE trial (A Randomized Trial of Induction Versus Expectant Mangement). Joy was in the air! The moment we have all been waiting for is finally here. We had high spirits and we were eagerly waiting to welcome our first child, the first grandchild in my wife’s family. The induction process went smoothly in the first 24 h, and with every hour passing, I was getting closer to holding my daughter. However, my wife developed high fevers (39–40 °C) and rigors. My heart sank as my wife was diagnosed with chorioamnionitis or Triple-I, a diagnosis that every OB and neonatologist fears.

A decision was made by the OB team to continue the induction process, up to hopefully a vaginal delivery based on reassuring fetal heart rates. But the fevers did not relent. My wife, despite antipyretics and antibiotics, continued to spike high fevers. As I continued to watch my wife struggle with labor, I grew more and more anxious. After 2 days of induction, because of arrest of descent, a cesarean section (CS) was performed.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD